Sign in

Trial result ·

Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This study tested a drug called amlenetug in people with multiple system atrophy (MSA). The drug is an antibody aimed at clumps of a protein called α-synuclein. The trial took place at 18 sites in the USA and Japan. People aged 40 to 75 had had movement signs for 5 years or less. By chance, each person got the drug or a dummy drug, called placebo. Doses went into a vein every 4 weeks, for 48 to 72 weeks. Neither the people nor the staff knew who got which.

What they found

Of 64 people who joined, 61 got a dose: 40 drug, 21 placebo. The trial did not reach its main goal. There was a hint that MSA got worse more slowly with the drug. But this result could have been due to chance. Health problems during the trial came at similar rates in both groups. Common ones were COVID-19, back pain, headache and urine infections. Each group had the same number of deaths. Only one death, in the placebo group, may have been linked to the dose given.

What it means for patients

The drug did not clearly slow MSA in this trial. Still, the authors saw a possible slowing of the disease. They also felt the drug's safety was acceptable. They say this supports testing it further in a phase 3 trial. An open part of the trial, where all know the drug, is still going on.

Why it is not certain yet

The main result did not pass the bar the team set in advance. So the hint of benefit may not be real. Only 61 people got a dose, and fewer got placebo than the drug. 48 of 61 people finished the blinded part. People came only from the USA and Japan.

The registered trial

The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.

Source

Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial.

PubMed · PMID 42044642

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Multiple system atrophy publications